ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
Clinical trial NCT02029443 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02029443
- Sponsor
- Acerta Pharma BV
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-01-30
- Primary completion
- 2021-07-15
- Enrollment
- 306
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.